AdventHealth is the first in the U.S. and the only health system in Florida to offer this new ‘precision medicine’ treatment.
A new way of treating bladder cancer is now available to patients in Central Florida via a Phase II randomized trial at the AdventHealth Cancer Institute. This is the only site in Florida, and the first in the U.S., to open this groundbreaking treatment, known as the INTerpath-005 V940 mRNA vaccine Phase II trial.
“This vaccine is precision medicine at its best,” Dr. Guru Sonpavde, a medical oncologist at the AdventHealth Cancer Institute, as well as a member of the trial’s global steering committee, recently told Central Florida Health News. “Unlike most trials where all patients receive one specific drug, some of the patients in this trial will receive a new drug customized to target the specific mutated proteins only found in the cancer cells of that patient.”
Participants will receive pembrolizumab (KEYTRUDA) combined with the new customized immunotherapy injection. KEYTRUDA alone has previously improved outcomes following surgical removal of aggressive muscle-invasive urothelial cancer.
“This V940 drug is exciting in that it codes for 34 neoantigens (which are new mutated proteins) found only in cancer cells and this is injected into the patient intramuscularly every three weeks for up to nine times,” Sonpavde discussed with Becker’s on their Healthcare podcast. “This (drug) is extremely specific immunotherapy which looks highly promising.”
Sonpavde believes this trial offers a tailored treatment against bladder cancer.
”I’m optimistic the combination drug treatment, the V940 vaccine plus KEYTRUDA, in this trial will be safe and successful and will lead to a Phase III trial,” he recently told the American Hospital Association.
He envisions this custom treatment to become more widely available worldwide soon. Bladder cancer patients don’t have to wait years for access, the trial is now open. Patients need a referral and should ask their doctor if they’re interested.
For more information, contact the AdventHealth Clinical Research GU Coordinator at ORL.GU.ClinicalTrials@AdventHealth.com.
6 items. To interact with these items, press Control-Option-Shift-Right Arrow.
Final steel beam marks key step in AdventHealth Daytona Beach expansion
Local leaders, officials, and construction workers gathered today to commemorate a major milestone in the expansion underway at AdventHealth Daytona Beach: placing the final steel beam.
New physician is joining AdventHealth’s growing Primary Care team
AdventHealth is excited to introduce Eugenio L. Menendez, DO, FACP, to our community of care. He is joining the team at AdventHealth Medical Group Family Medicine at Hendersonville* following the...
New visitor shuttle unveiled at AdventHealth Heart of Florida
AdventHealth Heart of Florida and AdventHealth Polk Foundation leaders are delighted to unveil a new courtesy visitor shuttle meant to enhance accessibility and comfort for patients.
Orthopedic surgeon returns to AdventHealth
Dr. Jeffrey Keen, a board-certified orthopedic surgeon specializing in adult reconstruction, orthopedic surgery, robotic-assisted surgery, and sports medicine, has returned to AdventHealth Medical...
Hundreds of transplant patients and their families reunite with AdventHealth Transplant Institute caregivers
In recognition of National Donate Life Month, nearly 300 transplant patients and their families enjoyed AdventHealth’s 2025 transplant reunion.
Ashley and Jimmy celebrate life together after kidney donation
According to the National Kidney Foundation, more than 101,000 people are currently on the organ transplant list in need of a new kidney. However, only about 17,000 transplants happen each year —...